文献速递眼底病与葡萄膜炎青光眼

2014至2020年眼科研究产业支付趋势与特征

Trends and Characteristics of Industry Payments for Ophthalmology Research From 2014 to 2020.
PubMed 文献 · JAMA Ophthalmol · 2022-10-13

这项横断面研究利用美国联邦医疗保险与医疗补助服务中心的开放支付数据库,分析了2014至2020年眼科医生获得产业研究支付的情况。产业支付分布不均,前10%的眼科医生获得65.7%的经费。

要点

  • 产业支付高度集中:108家制造商中前15家占93.9%,前10%眼科医生获得65.7%的经费。

核心结论

  • 眼科产业资助研究规模广泛且范围扩大,但分布不均。
  • 产业研究资助总额低于公共资助,但2014至2020年增长更快。
  • 产业资助在眼科研究中的重要性日益增加,但也可能给与产业合作的临床医生带来伦理挑战。

研究设计与样本

  • 横断面研究,使用美国联邦医疗保险与医疗补助服务中心的开放支付数据库识别2014至2020年获得产业研究支付的所有眼科医生。
  • 将产业资助与美国国家眼科研究所的公共研究资助进行比较。
  • 分析支付金额与分布、赞助制造商及研究产品,并采用正式趋势分析描述总体及个体层面资金变化。

主要发现

  • 2014至2020年,2102名眼科医生获得产业研究支付共计825417233美元。
  • 产业资助从2014年的62924525美元增至2020年的190714508美元,增长203%(P = .01)。
  • 美国国家眼科研究所研究资助总额为5003407764美元,从2014年的701313262美元增至2020年的747929556美元,增长6.6%(P = .04)。
  • 产业资助占所有医学研究资助的比例从2014年的1.2%升至2020年的3.2%(P = .04)。
  • 108家制造商中前15家占资助的93.9%;前10%的眼科医生(210人)获得全部研究经费的65.7%(542299121美元)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Characterizing industry-ophthalmology collaborations in research can highlight current areas of focus, improve transparency, and identify potential sources for conflicts of interest. OBJECTIVE: To assess the trends and characteristics in research payments reported from industry to ophthalmologists from 2014 to 2020. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the Centers of Medicare & Medicaid Services' Open Payments database (OPD), which contains public records of payments between industry and physicians, to identify all ophthalmologists who received industry payments for research purposes between 2014 and 2020. Industry funding was compared with public research funding by the National Eye Institute. MAIN OUTCOMES AND MEASURES: The value and distribution of payments, sponsoring manufacturers, and research products were assessed. Changes in aggregate and per individual-level funding were characterized using formal trend analysis. RESULTS: From 2014 to 2020, 2102 ophthalmologists were reported to have received $825 417 233 in industry research payments. Industry funding increased 203% from $62 924 525 in 2014 to $190 714 508 in 2020 (P = .01). Comparatively, total National Eye Institute research funding during the same period was $5 003 407 764 and increased 6.6% from $701 313 262 in 2014 to $747 929 556 in 2020 (P = .04). The share of all medical research funding from industry directed specifically toward ophthalmology research increased from 1.2% in 2014 to 3.2% in 2020 (P = .04). The distribution of industry payments was skewed, with the top 15 of 108 manufacturers accounting for 93.9% of funding. The top 10% of ophthalmologists (210) were reported to have received 65.7% of all research dollars ($542 299 121). The highest funded research products were anti-vascular endothelial growth factor agents, glaucoma treatments, and intraocular lenses. CONCLUSIONS AND RELEVANCE: Although unequal in distribution, industry-funded research in ophthalmology is extensive and increasing in scope. Industry funding for research is less than that of public funding; however, industry funding increased faster between 2014 and 2020. Results of this study highlight the increasing importance of industry funding in ophthalmology research, but it may also present ethical challenges for clinicians collaborating with industry.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kalva P, Kakkilaya A, Mekala P, et al. Trends and Characteristics of Industry Payments for Ophthalmology Research From 2014 to 2020. JAMA Ophthalmol. 2022. PMID: 36227612. doi:10.1001/jamaophthalmol.2022.3986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。